Discover and read the best of Twitter Threads about #UrologyJournalClub
Most recents (1)
In this #UrologyJournalClub we discuss and summarize the Belzitufan Phase 2 trial for renal masses in patients with Von Hippel-Lindau (VHL) disease published @NEJM which led to the approval of Welireg.
🔗 pubmed.ncbi.nlm.nih.gov/34818478/
💾urologiabe.files.wordpress.com/2021/11/urolog…
1/
@VPrasadMDMPH
🔗 pubmed.ncbi.nlm.nih.gov/34818478/
💾urologiabe.files.wordpress.com/2021/11/urolog…
1/
@VPrasadMDMPH
📃 phase 2, single arm, open label
N=61
Pts with VHL and renal masses (assumed to be renal cell carcinoma, biopsy not required).
Most pts had other VHL-related tumors simultaneously but these were not considered for inclusion or exclusion criteria but measured either way.
2/
N=61
Pts with VHL and renal masses (assumed to be renal cell carcinoma, biopsy not required).
Most pts had other VHL-related tumors simultaneously but these were not considered for inclusion or exclusion criteria but measured either way.
2/
This study found an objective response rate of 49% (quite impressive for a drug in an orphan disease), another 49% of patients showed stable disease and only 3 patients had progression.
3/
3/
